743
Participants
Start Date
July 31, 2004
Primary Completion Date
October 31, 2005
Study Completion Date
October 31, 2005
AzaSite
AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
Tobramycin
Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
Huntington Medical Group, Huntington Station
Irving Weinberger, MD, Pittsburgh
Cornerstone Eye Care, High Point
Southern Eye Associates, PA, Greenville
Advanced Eye Care, Panama City
Tukoi Institute for Clinical Research, North Miami Beach
Presidential Eye Center, West Palm Beach
Alan Shuster, MD, Jupiter
Palm Beach Eye Associates, Atlantis
The Eye Associates, Bradenton
Pasco Eye Institute, New Port Richey
Renaissance Center, Birmingham
Medisphere Medical Research Center, LLC, Evansville
Ophthalmology Associates, Creve Coeur
Research Eye Care Center, Kansas City
Mason Eye Institute, Columbia
Hutchinson Clinic, Hutchinson
Corona Research Consultants, Inc., El Paso
Children's Eye Physicians, Littleton
Jon Fishburn, MD, Boise
Cottonwood Ophthalmology Associates, Murray
Eye Health Northwest, Portland
Wenatchee Valley Medical Center, Wenatchee
Rockwood Clinic, PS-Eye Center, Spokane
Massachusetts Eye and Ear Infirmary, Boston
Ophthalmology Associates, Princeton
Merck Sharp & Dohme LLC
INDUSTRY